Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Isatuximab Approved First-Line for Transplant-Ineligible MM
The Food and Drug Administration expanded the label of isatuximab-irfc (Sarclisa — Sanofi-Aventis) on September 20 to include treatment with bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma (MM) ineligible for autologous stem cell transplant. The new…
English